SCHEMBL21887763

SCHEMBL21887763

COc1cc2c(c(N3CCNCC3)c1OC)CC(Cc1ncccc1C(F)(F)F)C2=O

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 1/20 0.40
▸ HTR2C P28335 2/20 0.38
▸ ACHE P22303 3/20 0.37
▸ BCHE P06276 2/20 0.37
▸ ACVR1 Q04771 2/20 0.37
▸ ALK Q9UM73 3/20 0.37
▸ NCF1 P14598 1/20 0.37
▸ FLT4 P35916 1/20 0.36
▸ PTK2 Q05397 1/20 0.36
▸ SCN9A Q15858 1/20 0.36
▸ CYP19A1 P11511 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ ACVR1B P36896 1/20 0.35
▸ TGFBR1 P36897 1/20 0.35
▸ HTR2A P28223 1/20 0.35
▸ EGFR P00533 1/20 0.35
▸ PDE4D Q08499 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16552586 0.92 ACHE (0.39) ACHEBCHESCN9ACYP19A1CYP1A2
SCHEMBL16552712 0.91 ULK1 (0.38) ACHEBCHEPTK2SCN9ACYP19A1
SCHEMBL16552886 0.91 ACHE (0.39) HTR2CACHEBCHECYP19A1HTR2A
SCHEMBL21887762 0.89 ACHE (0.46) ACHEBCHEACVR1NCF1CYP19A1
SCHEMBL16552698 0.84 ACHE (0.46) EPHX2ACHEBCHENCF1PDE4D
SCHEMBL22212700 0.84 ACVR1 (0.35) HTR2CACHEBCHEACVR1ALK
SCHEMBL16558731 0.79 ACHE (0.49) ACHEBCHECYP19A1HTR2APDE4D
SCHEMBL16552907 0.79 ACHE (0.46) ACHEBCHECYP19A1PDE4D
SCHEMBL16552816 0.79 SSTR4 (0.40) ACHEBCHEPTK2PDE4D
SCHEMBL16558732 0.79 ACHE (0.48) ACHEBCHECYP19A1PDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3044223-B1 2,3-DIHYDRO-1H-INDEN-1-ONE DERIVATIVES AS RETINOIC ACID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA) ANTAGONISTS FOR TREATING MULTIPLE SCLEROSIS ARRIEN PHARMACEUTICALS LLC (US) 2020-04-01 — — EP disclosed
Send feedback